Propranolol hydrochloride, a non-selective beta-adrenergic blocker, has been widely used in the treatment of hypertension, angina pectoris, pheochromocytoma and cardiac arrhythmias (1). Because of its relatively short plasma half-life, patients are routinely asked to take propranolol hydrochloride in divided daily doses, once every 6 to 8 h. Such frequent drug administration may reduce patient compliance and therapeutic efficacy (2). In recent years, slow or sustained release formulations of propranolol hydrochloride have become available with claims that these formulations maintain beta adrenoreceptor blockade throughout a 24 h period and enable the drug to be given once daily (3).

The multilayered tablet concept has been long utilized to develop sustained release formulations. Such a tablet has a fast releasing layer and may contain bi- or triple layers...
to sustain the drug release (4). The pharmacokinetic advantage relies on the fact that drug release from fast releasing granules leads to a sudden rise in the blood concentration. However, the blood level is maintained at steady state as the drug is released from the sustaining granules. Among the different polymers, Eudragit (5, 6) and ethylcellulose (7–11) have been used successfully to obtain appropriate sustained release matrix formulations of different materials. The present study aims at formulating bilayered tablets of propranolol hydrochloride with a fast release layer using sodium starch glycolate and a sustaining layer using hydrophobic polymers like ethylcellulose, Eudragit RLPO and Eudragit RSPO.

EXPERIMENTAL

Materials

Propranolol hydrochloride was obtained as a gift sample from Natco Pharma, India. Ethylcellulose (15 cP) was procured from Genuine Chemicals, India. Eudragit RLPO [poly (ethyl acrylate, methyl methacrylate, trimethylaminoethyl-methacrylate chloride)(1:2:02)] and Eudragit RSPO [poly(ethyl acrylate, methyl methacrylate, trimethylamino methyl methacrylate chloride) (1:2:01)] were procured from S D Fine Chemicals, India. Starch was obtained from Meghana Products, India, talc was procured from Swastik Pharmaceuticals, India, and magnesium stearate was procured from Nice Chemicals, India. Other materials and solvents used were of analytical grade.

Preparation and characterization of bilayer tablets

The bilayer tablets of propranolol hydrochloride were prepared by the wet granulation method. The drug and polymers for both fast release and sustaining layer were passed through a 180-µm sieve before their use in the formulation.

Formulation of the fast release layer. – The dose in the formulation for fast release was 25 mg, the maintenance dose or sustained dose (55 mg) of propranolol hydrochloride was calculated as per the reported method (12, 13). The fast release granules were prepared by wet granulation technique by blending propranolol hydrochloride uniformly with sodium starch glycolate using starch paste (10% m/m) as binder as per the formulae given in Table I. The cohesive mass obtained was passed through a 1000 µm sieve, dried at 60 °C for 1 h to give a moisture content of 4–6%, determined on an IR moisture balance (Macro Scientific Works, India). The granules were again passed through a 1000-µm screen to break up agglomerates. The granules were mixed with talc and magnesium stearate.

Formulation of the sustained release layer. – The sustaining granules were formulated by the wet granulation technique, mixing propranolol hydrochloride uniformly with Eudragit RLPO, Eudragit RSPO or ethylcellulose. Lactose was mixed with the above drug and polymer mixture. Starch paste (10% m/m) was used as binder as per the formulae given in Table II. The sustaining granules were also subjected to similar processing steps as the fast releasing granules.
Characterization of granules. – Prior to compression, granules were evaluated for their characteristic parameters, such as tapped density, Carr’s index and angle of repose (15).

Carr’s compressibility index was calculated from the bulk and tapped densities (14) using a digital tap density apparatus (Electrolab Ltd, India).

Compression of bilayer tablet. – The quantity of granules for the sustained release layer was compressed lightly using a single punch-tableting machine (Cadmach Machinery Co Pvt. Ltd., India) equipped with 6.5-mm round, flat and plain punches. Over this compressed layer, the required quantity of the fast release layer was placed and compressed to obtain hardness in the range of 5–7 kg cm\(^{-2}\) to form a bilayer matrix tablet.

Physical tests for the bilayer tablets. – Standard physical tests for the bilayer matrix tablets were performed (16) and average values were calculated. Mass variation was determined by weighing 20 tablets individually, the average mass was calculated and the percent variation of each tablet was calculated. Hardness was determined by taking 6 tablets from each formulation using a Monsanto hardness tester (Electrolab Pvt. Ltd., India).

<table>
<thead>
<tr>
<th>Table I. Formulation of the fast release layer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ingredient</td>
</tr>
<tr>
<td>------------</td>
</tr>
<tr>
<td>Propranolol hydrochloride</td>
</tr>
<tr>
<td>Sodium starch glycolate</td>
</tr>
<tr>
<td>Starch paste (10%, m/m)</td>
</tr>
<tr>
<td>Magnesium stearate</td>
</tr>
<tr>
<td>Talc powder</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table II. Formulation of the sustained release layer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ingredient</td>
</tr>
<tr>
<td>Propranolol hydrochloride</td>
</tr>
<tr>
<td>Ethyl cellulose</td>
</tr>
<tr>
<td>Eudragit RSPO</td>
</tr>
<tr>
<td>Eudragit RLPO</td>
</tr>
<tr>
<td>Lactose</td>
</tr>
<tr>
<td>Starch paste (10%)</td>
</tr>
<tr>
<td>Talc</td>
</tr>
<tr>
<td>Magnesium stearate</td>
</tr>
</tbody>
</table>
In the friability test, the average of pressure (kg cm\(^{-2}\)) applied for crushing the tablet was determined. Friability was determined by first weighing 10 tablets after dusting and placing them in a friability tester (Electrolab Pvt. Ltd., India), which was rotated for 4 min at 25 rpm. After dusting, the total remaining mass of the tablets was recorded and the percent friability was calculated.

**Drug content uniformity.** – Ten tablets were finely powdered and an amount equivalent to 40 mg of propranolol hydrochloride was accurately weighed and transferred to a 100 mL volumetric flask, then 70 mL of methanol was added. The flask was shaken for 10 min. Finally, the volume was made up to the mark with methanol. The mixture was then filtered and 1 mL of the filtrate was suitably diluted with methanol to obtain a solution containing about 40 µg mL\(^{-1}\) of propranolol hydrochloride and analyzed for propranolol hydrochloride content (17) at 290 nm using a double beam UV/Visible spectrophotometer (Elico Ind Ltd, India) and methanol as blank.

**In vitro dissolution**

Release of propranolol hydrochloride was determined using a USP 24 (17) six stage dissolution rate test apparatus 1 (Labindia Instruments Pvt. Ltd, India) at 50 rpm. The dissolution was studied using 900 mL of simulated gastric fluid (without enzyme, pH 1.2) for the first 2 h and followed by simulated intestinal fluid (without enzyme, pH 7.2) for the remaining hours (17). The temperature was maintained at 37 ± 0.2 °C. The sample (5 mL) was withdrawn at different time intervals, *i.e.* 5, 15, 30, 60, 120, 180, 240, 300, 360, 480, 600 and 720 min, filtered through Whatman filter paper (Auroco Pvt Ltd, Thailand) and replaced by an equal volume of dissolution medium. Samples were suitably diluted and analyzed for propranolol hydrochloride content at 290 nm.

---

**Table III. In-vitro dissolution kinetics of propranolol hydrochloride**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Drug release kinetics (R)</th>
<th>Peppas release exponent (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Zero-order</td>
<td>First-order</td>
</tr>
<tr>
<td>RSPO 1:0.5</td>
<td>0.984</td>
<td>0.969</td>
</tr>
<tr>
<td>RSPO 1:1</td>
<td>0.965</td>
<td>0.964</td>
</tr>
<tr>
<td>RSPO 1:1.5</td>
<td>0.979</td>
<td>0.952</td>
</tr>
<tr>
<td>RLPO 1:0.5</td>
<td>0.991</td>
<td>0.964</td>
</tr>
<tr>
<td>RLPO 1:1</td>
<td>0.959</td>
<td>0.939</td>
</tr>
<tr>
<td>RLPO 1:1.5</td>
<td>0.979</td>
<td>0.952</td>
</tr>
<tr>
<td>EC 1:0.5</td>
<td>0.983</td>
<td>0.969</td>
</tr>
<tr>
<td>EC 1:1</td>
<td>0.967</td>
<td>0.945</td>
</tr>
<tr>
<td>EC 1:1.5</td>
<td>0.977</td>
<td>0.963</td>
</tr>
</tbody>
</table>
**Kinetic analysis of dissolution data**

The rate and mechanism of release of propranolol hydrochloride from the prepared bilayer tablets were analyzed by fitting the dissolution data into the zero-order equation (18):

\[ Q = k_0 t \]

where \( Q \) is the amount of drug released at time \( t \), and \( k_0 \) is the release rate constant, fitted to the first order equation (19):

\[ \ln (100–Q) = \ln 100 – k_1 t \]

where \( k_1 \) is the release rate constant. The dissolution data was fitted to the Higuchi’s equation (20)

\[ Q = k_2 t^{1/2} \]

where \( k_2 \) is the diffusion rate constant.

The dissolution data was also fitted to the well known equation (Korsmeyer equation), which is often used to describe the drug release behavior from polymeric systems (21):

\[ \log \left(\frac{M_t}{M_\infty}\right) = \log k + n \log t \]

where \( M_t \) is the amount of drug released at time \( t \), \( M_\infty \) is the amount of drug release after infinite time, \( k \) is a release rate constant incorporating structural and geometric characteristics of the tablet and \( n \) is the diffusional exponent indicative of the mechanism of drug release.

**FT-IR study**

Infrared spectrum was taken (FT-IR, Spectrum RX 1, Perkin Elmer Ltd, Switzerland) by scanning the sample in potassium bromide discs. The samples of pure drug and granules containing different polymers were scanned individually.

**Statistical analysis**

*In vitro* release data of propranolol hydrochloride from bilayer tablets of optimized formulations were subjected to the analysis of variance (ANOVA) at two different time intervals, 15 min and 12 h.
RESULTS AND DISCUSSION

The prepared bilayer tablets were evaluated for various physical properties. The bulk densities for the granules of various formulations ranged between 0.87 ± 0.14 and 2.42 ± 0.42 g mL⁻¹, as determined by the tap method. This value of bulk density indicates good packing character. The compressibility index (CI) for all the formulations was found to be below 15%, indicating desirable flow properties (14). The flow properties of granules were further analyzed by determining the angle of repose for all granules; it ranged between 21.32 ± 0.58 to 25.03 ± 0.23°. The value indicates good flow property (15) of granules with Eudragit RLPO, Eudragit RSPO and ethylcellulose as matrix material.

All the batches of tablets were produced under similar conditions to avoid processing variables. Mass of the bilayer tablets was 201 ± 12 mg, hardness was 5.2 ± 1.2 kg cm⁻² and thickness was 2.9 ± 0.1 mm. The percentage friability of all the formulations was 0.5 ± 0.3%. Values of the hardness test and percent friability indicate good handling properties of the prepared bilayer tablets. The drug content uniformity in the bilayer matrix tablets was 96.5 ± 4.9%.

The FT-IR spectrum of propranolol hydrochloride, shown in Fig. 1, revealed the presence of peaks at 2965.1 cm⁻¹ due to the presence of a secondary amine group, peaks at 3283.7 cm⁻¹ due to the hydroxyl group (secondary), the aryl alkyl ether displayed a stretching band at 1268 cm⁻¹ and the peak at 797.9 cm⁻¹ was due to α-substituted naphthalene. The FT-IR spectra of propranolol hydrochloride granules containing different types of polymer showed a broadening of peaks at 3283 cm⁻¹ frequency due to extensive hydrogen bonding. Major frequencies of functional groups of pure drug remain intact in granules containing different polymers; hence, there is no major interaction between the drug and polymers used in the study.

![Fig. 1. FT-IR spectra of pure propranolol hydrochloride (a) and propranolol hydrochloride granules containing different polymers: ethylcellulose (b), Eudragit RSPO (c), and Eudragit RLPO (d).](image)
The release of propranolol hydrochloride from the prepared formulations was analyzed by plotting the cumulative percent drug released vs. time as shown in Figs. 2a–c. Simple visual observation of the plot shows an initial burst effect. From all the formulations, over 30% of the propranolol hydrochloride was released within the first 15 min of the dissolution study. This initial high amount of propranolol hydrochloride release can be attributed the immediate release layer of the formulation. Further release of propranolol hydrochloride was studied for 12 h.

Ethylcellulose has been used as release retardant polymer in controlled release dosage forms (8, 22, 23). EC reduces the drug release due to a reduction in the penetration of the solvent molecules into the system because of the hydrophobic nature of ethylcellulose present on the surface of the tablet, i.e. the rate of release is controlled by the permeability of matrix structure (24). As the proportion of ethylcellulose increase, the release process of propranolol hydrochloride decreases (Fig. 2a). Fig. 2a shows that formulation EC 1:0.5 could not sustain the release beyond 7 h whereas formulations EC 1:1 and EC 1:1.5 showed the desired release profile over the test period of 12 h. Therefore, formulation EC 1:1 was selected as the optimized formulation keeping in view the minimum

Fig. 2. Cumulative propranolol hydrochloride released vs. time (mean ± SD, n = 3) from: a) EC, b) Eudragit RSPO, c) Eudragit RLPO.
amount of ethylcellulose required to sustain the release for a period of 12 h. In this selected formulation, the calculated regression coefficients for Higuchi, zero order and first order models were 0.991, 0.967 and 0.945, respectively. Therefore, the release seems to fit the Higuchi model (Fig. 3). To explore the release pattern, results of the in vitro dissolution data were fitted to the Korsmeyer and Peppas equation (25), which characterizes the transport mechanism. The value of release exponent (n) for the optimized formulation EC 1:1 was 0.585, indicating release governed by non-Fickian diffusion (Fig. 4).

Similarly, formulations containing Eudragit RSPO (RSPO 1:0.5 and RSPO 1:1) and Eudragit RLPO (RLPO 1:0.5 and RLPO 1:1) were unable to sustain the release of drug for the desired period of 12 h (Fig. 2b,c). However, the formulation RSPO 1:1.5 and RLPO 1:1.5 could sustain the release for 12 h. Hence, these two were selected as optimized formulations. The calculated regression coefficients for Higuchi, zero order and first order models for the last two were 0.988, 0.979 and 0.952, and 0.988, 0.979 and 0.952, respectively. Therefore, the release seems to fit the Higuchi model (Fig. 3). The Korsmeyer and
Peppas release exponent ($n$) for formulation RSPO 1:1.5 was 0.610 and for RLPO 1:1.5 0.604, indicating release governed by non-Fickian diffusion (Fig. 4). The drug release from formulation RSPO 1:1.5 was less compared to RLPO 1:1.5, because Eudragit RLPO tends to swell more than Eudragit RSPO in aqueous medium (26, 27). Also, Eudragit RLPO is more permeable to aqueous medium than Eudragit RSPO (28).

All the formulations prepared with ethycellulose, Eudragit RSPO and Eudragit RLPO predominantly followed the Higuchi model and non-Fickian diffusion after the initial burst release. In all the three polymers, permeability to water was the common rate controlling factor.

Analysis of variance (ANOVA) showed no significant difference in the amount of drug released after 15 min from optimized formulations EC 1:1, RSPO 1:1.5 and RLPO 1:1.5; however, significant differences ($p < 0.05$) were observed for the amount of drug released after 12 h from the same formulations.

CONCLUSIONS

The present research was carried out to develop a bilayer tablet of propranolol hydrochloride using superdisintegrant sodium starch glycolate for the fast release layer and ethylcellulose, Eudragit RLPO and Eudragit RSPO for the sustaining layer. Bilayer tablets showed an initial burst effect to provide the loading dose of the drug, followed by sustained release for 12 h, indicating a promising potential of the propranolol hydrochloride bilayer tablet as an alternative to the conventional dosage form.

REFERENCES

5. J. P. Vercammen, D. Dauwe and P. Broen, Possibility of use of Eudragit RS as a sustained release matrix agent for the incorporation of water soluble active compounds at high percentages, STP Pharma. Sci. 7 (1997) 491–497.


Razvoj i vrednovanje dvoslojnih tableta propranolol hidroklorida

CHINAM NIRANJAN PATRA, ARETHI BHARANI KUMAR, HEMANT KUMAR PANDIT, SATYA PRAKASH SINGH i MEDURI VIMALA DEVI

U radu je opisan razvoj dvoslojnih tableta propranolol hidroklorida, koristeći superdezintegrator škrob glikolat natrij u sloju za brzo oslobađanje i polimere koji se ne miješaju s vodom (etilceluloza, Eudragit RLPO i Eudragit RSPO) u sloju za usporeno oslobađanje. In vitro oslobađanje prati Higouchijev model, dok mehanizam kontroliranog oslobađanja ne slijedi Fickov zakon poslije početnog naglog oslobađanja. FT-IR studije ukazuju da nema interakcije između ljekovite tvari i polimera upotrebjenih u oblikovanju. Statistička analiza (ANOVA) nije pokazala značajne razlike u kumulativnoj količini oslobađenog lijeka iz optimiranih formulacija poslije 15 minuta, ali polije 12 h još se ta količina značajno razlikovala ($p < 0.05$).

Ključne riječi: propranolol hidroklorid, dvoslojne tablete, škrob glikolat natrij, polimeri koji se ne miješaju s vodom, statistička analiza

P.G. Department of Pharmaceutics, College of Pharmaceutical Sciences, Berhampur-760002, Orissa, India